



Vicore Pharma publishes prospectus in connection with its listing on Nasdaq Stockholm

Gothenburg, September 16, 2019- On September 11, 2019, Vicore Pharma Holding AB (publ) ("Vicore" or the "Company") announced that Nasdaq Stockholm's listing committee had approved that the Company's shares are admitted to trading on Nasdaq Stockholm's main market. Today, on September 16, 2019, the prospectus that has been prepared in connection with the listing was approved and registered by the Swedish Financial Supervisory Authority and is now available on Vicore's website, www.vicorepharma.com.

The first day of trading on Nasdaq Stockholm's main market is September 27, 2019. The last day of trading on Nasdaq First North Growth Market is September 26, 2019.

For further information, please contact:

Carl-Johan Dalsgaard, CEO tel: +46 (0)70 975 98 63, carl-johan.dalsgaard@vicorepharma.com

Hans Jeppsson, CFO, tel: +46 (0)70-553 14 65, hans.jeppsson@vicorepharma.com

The information was submitted for publication through the agency of the contact persons set out above, at 17.30 CEST on September 16, 2019.

About Vicore Pharma Holding AB (publ)

Vicore Pharma is a Swedish rare disease pharmaceutical company focused on interstitial lung diseases and related indications. The company currently has two drug development programs, VP01 and VP02.

VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis ("IPF") and diffuse systemic sclerosis ("dSSc"). VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an "IMiD"). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which has a significant high unmet need. The VP01 Phase IIa studies in IPF and dSSc patients are expected to be initiated during the second half of 2019. VP02 is entering a phase of optimization of formulation before local tolerability studies will commence. The first clinical studies with VP02 are expected to start in 2020.

The company's share (VICO) is listed for trading on Nasdaq First North Growth Market in Stockholm. The company's certified adviser is Erik Penser Bank, telephone: +46 8 463 83 00, e-mail: certifiedadviser@penser.se. For more information, see www.vicorepharma.com